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journal homepage: www.ejves.comEditorialCarotid Revascularization to Prevent StrokeTrial after trial, carotid angioplasty with stenting (CAS) has
shown inferior results compared to carotid endarterectomy (CEA)
in terms of prevention of stroke and stroke-related death. The Inter-
national Carotid Stenting Study (ICSS), still the largest randomized
trial in recently symptomatic patients, reported a signiﬁcantly lower
peri-procedural risk for patients undergoing CEA than for patients
randomized to CAS (30 day rate of death/stroke 7.4% after CAS vs
3.4% after CEA (per protocol analysis HR 2.16 (95% CI 1.4–3.3)).1 At
ﬁrst glance, themain conclusions fromtheCarotidRevascularization
Endarterectomy vs. Stenting Trial (CREST), which included both
symptomatic and asymptomatic patients, did suggest equivalence
of CAS and CEA, with no signiﬁcant difference between CAS and
CEA in the rates of the primary composite endpoint 30 day risk of
death/stroke/myocardial infarction (MI), or any ipsilateral stroke
within four years (7.2% and 6.8%, respectively (HR with CAS 1.11;
95% CI 0.81 to 1.51; p ¼ 0.51). However, CREST also showed a signif-
icantly higher peri-operative stroke rate for CAS 4.1% vs. 2.3% after
CEA (HR 1.79 (95% CI 1.14–2.82)).2 The similar beneﬁt between
both procedures for the primary endpoint, was mainly driven by
the intensively discussed and criticized inclusion of “silent” or
“biochemical” MI in the composite endpoint. Based on the primary
endpoint, CREST results were wrongly interpreted even in well
respected media, stating that “CAS and CEA were equally as safe
and effective in terms of stroke prevention”.3 In reality, ICSS and
CREST actually showed very similar results, namely twice as many
strokes associated with stenting as with endarterectomy. Further-
more, a pooled analysis of EVA-3S, SPACE, and ICSS showed substan-
tially more peri-procedural deaths (RR 1.96 CI 1.04–3.72), and more
peri-procedural stroke and death (RR 1.78 CI 1.40–2.25) with CAS
thanwithCEA.4 Interestingly, thismeta-analysis observedheteroge-
neity between different age groups, with a signiﬁcant difference
recorded only between CAS and CEA in patients older than 70 years
(12.0% vs. 5.9%, risk ratio 2.04, 95% CI 1.48–2.82). In patients younger
than70years, nodifferencewasnotedbetweenCASandCEA, but the
95% conﬁdence interval (0.68–1.47) did not exclude a difference in
either direction. So, for symptomatic patients with carotid stenosis
>50% CAS is factually less safe and effective in terms of stroke
prevention, particularly for patients older than 70 years.4
How can trial results be interpreted so differently? While in
European guidelines the results of these trials and meta-
analyses led to the conclusion that CEAwas safer than CAS recom-
mending CEA as the treatment of choice for recently symptomatic
patients,5 surprisingly, the American Heart Association (AHA)DOI of original article: 10.1016/j.ejvs.2011.12.006.
1078-5884/$ – see front matter  2011 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2011.12.014released its 2011 recommendations for the treatment of patients
presenting with TIA or minor stroke considering CAS as an alter-
native to CEA for symptomatic patients at average or low risk
with >50% angiographic stenosis.6 Although stating to include
“all data available at that time” in their analysis, the AHA omitted
any reference to the ICSS trial, while including CREST data. For
unknown and unreported reason ICSS data were completely
ignored despite the fact that CREST results were released one
year after publication of ICSS. If the United States Center for Medi-
care and Medicaid services (CMS) in considering a proposal to
allow wider indications for reimbursement of CAS, uncritically
follows AHA guidelines, it clearly might not get the complete
and objective information needed for a balanced decision. In the
letter by Abbott et al. a multidisciplinary collaboration of world
leading stroke physicians and vascular and endovascular surgeons
plea against the proposed use of CAS in asymptomatic or low risk
symptomatic patients.7 The push for wider indications for CAS in
the US guidelines is merely based on the results from CREST and
Sapphire trial.6,8 Sapphire randomized deemed high risk patients
but in fact included 70% of asymptomatic patients who can never
be at high risk for stroke by deﬁnition. However, as clearly out-
lined by Abbott et al., irrespective of symptomatic status, CAS in
CREST, was associated with about double the peri-procedural
rate of stroke or death compared to CEA.2,7 In using Sapphire
criteria, innocent readers might hail CAS as the treatment of
choice in the majority of these “high risk” patients. However,
treating asymptomatic patients by CAS because of clinical factors
that make them high risk for other events than stroke will do little
to reduce the overall risk of stroke in the general population. At
the level of procedural stroke risk as reported in Sapphire, all
potential beneﬁt from any intervention ceases, and neither
surgery nor angioplasty can ever prevent long-term stroke in
these asymptomatic patients.9 Clinicians that uncritically imple-
ment CAS justiﬁed on Sapphire outcomes deﬁnitely will not do
their patients any service.
In considering carotid revascularization in asymptomatic
patients, it is of utmost importance to realize that the natural risk
for stroke has declinedwith the introduction of bettermedication.10
Furthermore, as noted after the publication of the landmark CEA
trials, procedural risksmay bemuch higher in “routine clinical prac-
tice” than within the conﬁnes of a randomized trial. The to be ex-
pected increases in the number of stenting interventions following
reimbursement in asymptomatic patients will do little to reduce
the incidence of stroke in the community, but it will contribute to
an ever increasing ﬁnancial burden to health care systems.d by Elsevier Ltd. All rights reserved.
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might have an advantage over the other, leaving space for applica-
tion of CAS in highly selected cases. The pro CAS movement keeps
indicating the possible improvements in endovascular techniques
that may lead to better outcomes in the near future. Strangely,
however, no structural analysis of stroke mechanism has been per-
formed within any trial so far. In our ongoing attempts to make
carotid revascularization a safer procedure, and to indicate treat-
ment on an individualized approach, understanding the underlying
pathophysiological mechanism of CAS related stroke is essential in
order to prevent those very same events in the future.
In summarizing the best available evidence at themoment, CEA is
clearly superior to CAS, independent of symptomstatus anddegree of
stenosis, when considering the most relevant endpoint – the occur-
rence of stroke or death. Hopefully, governmental institutions
responsible for reimbursement regulations will take careful notice
of the published evidence, and of the objectively stated andmultidis-
ciplinary supported considerations presentedbyAbbott et al. andwill
not extend reimbursement coverage for CAS to routine practice
management of asymptomatic or low risk patients.References
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